key: cord-0947474-rnzj2wva
authors: Chan, Ernest G.; Luketich, James D.; Sanchez, Pablo G.
title: Commentary: Recovery following COVID-19 infection: Are we truly ready for what is to come?
date: 2020-12-29
journal: JTCVS open
DOI: 10.1016/j.xjon.2020.12.016
sha: 96f2bbe7fc1fe2b50e6a1cc3bedc8cb87893cd7d
doc_id: 947474
cord_uid: rnzj2wva

nan

At the time of this editorial, the global spread of coronavirus-2 has affected over 72 million people and claimed 1.6 million lives. 1 The COVID-19 pandemic has tested our resilience, our sense of community, our ability to adapt, and to produce science and therapies with the goal of caring and rescuing patients from this devastating disease. Now with the first vaccines being distributed across the world we are filled with a sense of relief and hope.

Infection by the COVID-19 virus has a wide range of presentations from non-specific symptoms to interstitial pneumonia or severe acute respiratory syndrome (SARS-CoV-2). Two distinct pathophysiology phenotypes have been described for SARS-CoV-2. The first is the L form (low recruitability), which frequently responds well to non-invasive ventilation. The second is the more virulent H Form (high recruitability), which often requires invasive ventilatory support. 2 Mechanical ventilation strategies for SARS-CoV-2 rely on the principle of preventing alveolar overdistention. Extracorporeal membrane oxygenation (ECMO) can be instituted in cases in which severe hypoxemia persists in the setting of optimal ventilatory support, neuromuscular blockage and proning. A recent analysis from the Extracorporeal Life Support Organization (ELSO) COVID-19 registry evaluating outcomes of 1035 SARS-CoV-2 patients requiring ECMO support, reported that 57% were discharged alive with 30% going home or to an acute rehabilitation center, 10% to a long-term acute care facility and 17 % to another hospital. 3 These results are consistent with previous literature describing the use of ECMO for other causes of severe hypoxic respiratory failure.

While much as been reported about the initial hospital course of these patients, very little is known about the prognosis of SARS-CoV-2 survivors following initial discharge. An analysis describing index hospitalizations for COVID-19 to 132 Veteran Affairs Hospitals, reported that 27% of hospital survivors were readmitted or died within 90 days of discharge. 4

The current report by Mayer and colleagues addresses the concern of long-term outcomes by forming of the Outcomes and Recovery After COVID-19 Leading to ECMO (ORACLE) Group. 5 This group of five academic centers, have created a protocol follow-up of patients who recovered from COVID-19 infections following ECMO support. They found that 56% of patients had cognitive impairments and another third expressed both emotional and cognitive deficits during recovery from severe COVID-19 infections. While it is still early on in the follow-up period, Mayer and colleagues emphasize that many of these deficits in similar patients, such as the post-ARDS population, exhibit similar lingering effects even at 1 year follow-up. 6 As we continue to experience this evolving COVID-19 pandemic, Mayer and colleagues remind us of the need to be attentive and document the current events in order to prepare for the future.

One important point that will need to be addressed is the cost analysis and therefore allocation of our limited resources to the thousands of once critically ill COVID-19 patients who we were fortunate enough to treat. We applaud their efforts in creating the ORACLE group and we look forward to future analyses that will be possible due to their timely efforts.

J o u r n a l P r e -p r o o f

Center for Disease Control and Prevention: Coronavirus (COVID-19)

COVID-19 Phenotypes and Potential Harm of Conventional Treatments: How to Prove the Hypothesis. American journal of respiratory and critical care medicine

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System

Long-term Recovery of Survivors of COVID-19 treated with ECMO: The Next Imperative

Long-Term Cognitive Impairment after Critical Illness